|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In acromegaly, tumors secreting growth hormone had only an aneuploid DNA pattern in 41 per cent of the cases, whereas 67 per cent of the tumors with concomitant secretion of growth hormone and prolactin were aneuploid.
|
3993857 |
1985 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The third acromegalic brother had a normal GH value and evidence of panhypopituitarism; he had a small intrasellar tumor and a partially empty sella.
|
3950729 |
1986 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The presence of ir-PRL in the tumor tissue was always associated with positive PRL mRNA, indicating production of PRL in GH-secreting tumors.
|
2338572 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
One tumor contained cells immunoreactive for prolactin and human growth hormone; one tumor contained foci immunoreactive for the beta-subunits of luteinizing hormone and follicle-stimulating hormone; and the third tumor had no immunoreactive prolactin, human growth hormone, beta-subunits of thyroid-stimulating hormone, luteinizing hormone, or follicle-stimulating hormone, or the alpha-subunit.
|
2213163 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
These observations suggest that a considerable part of GH secreted from a GH-secreting pituitary adenoma is produced by a minority of the GH-secreting tumour cell population.(ABSTRACT TRUNCATED AT 250 WORDS)
|
2004472 |
1991 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
SSCP analysis revealed band shift in exon 8 in four GH- and in one GH/PRL-secreting tumors, and in exon 9 in one GH/PRL-secreting tumor.
|
1446784 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We conclude that there is, in general, little difference in the clinical and biochemical characteristics between gsp-positive and gsp-negative human pituitary GH-secreting tumors.
|
8396223 |
1993 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, the non-functioning and functioning pituitary tumors such as the prolactin and growth hormone secreting tumors express increased levels of the IL-6 gene.
|
7964988 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
For the first time, the expression of GH receptor gene in breast cancer cell lines and biopsies is demonstrated in this study, suggesting a GH-specific action in tumor development.
|
7794815 |
1995 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
One such mutation has been reported in a GH-producing tumour from a patient with multiple endocrine neoplasia type 1 (MEN 1) although mutations have not been reported in other tumours associated with MEN 1.
|
7598693 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Such a good GH suppressibility by somatostatin makes patients with gsp-mutated tumors the best candidates for medical treatment with somatostatin analogs.
|
8769403 |
1996 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
These results suggest that the G(S) alpha mutations of GH-secreting tumor are observed in Korean acromegalic patients with similar frequency to those of western countries.
|
8766942 |
1996 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Specifically, GHRH mRNA signal intensity was 1) linearly correlated with Ki-67 tumor growth fractions (r = 0.71; P < 0.001), 2) linearly correlated with preoperative serum GH levels (r = 0.56; p = 0.01), 3) higher among invasive tumors (P < 0.001), and 4) highest in those tumors in which post-operative remission was not achieved (P < 0.001).
|
9284826 |
1997 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Gsp mutation is one of the major intrinsic defects in the pathogenesis of growth hormone-secreting pituitary tumors and the identification of gsp mutation can be a reference for classification and prognosis of GH tumors.
|
11189233 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In summary, we have demonstrated that SUR mRNA expression is common in several types of silent pituitary adenomas and in functional tumors that secrete GH.
|
9666339 |
1998 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
It is possible that the elevated growth hormone levels are in part responsible for the rapid progression of the tumor.
|
9678473 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
When the authors used light microscopy, the tumor appeared to be a bimorphous mixed pituitary adenoma composed of two separate cell types: one cell population synthesized GH and the other ACTH.
|
9609310 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Activating mutations of the Gs alpha gene are associated with low levels of Gs alpha protein in growth hormone-secreting tumors.
|
9851782 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The pituitary tumours included 4 prolactinomas, 11 growth-hormone-secreting tumours and 8 non-functional tumours.
|
10097256 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We have investigated the cytogenetic alterations and DNA ploidy patterns of 12 sporadic pituitary adenomas, including 2 growth-hormone-secreting tumors, 1 prolactinoma, and 9 nonfunctional adenomas, by comparative genomic hybridization (CGH) and laser scanning cytometry (LSC).
|
10432933 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This effect is thought to be exerted through suppression of the pituitary growth hormone-hepatic insulin-like growth factor I (IGF-I) axis and direct inhibition of autocrine/paracrine production of IGF-I and -II in tumors.
|
10611309 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Reduction of growth hormone secretion and tumour regression in GH-secreting pituitary adenomas treated with long-acting somatostatin analogues varies widely.
|
10651751 |
2000 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In the present study we quantified SSTR2 and SSTR5 mRNA expression and the GH-suppressive effects of somatostatin-14; octreotide; a SSTR2-preferential compound, BIM-23197; a SSTR5-preferential compound, BIM-23268; and a new SSTR2- and SSTR5-bispecific compound, BIM-23244, in GH-secreting tumors classified as either full responders to octreotide (n = 5) or partially sensitive to octreotide (n = 5).
|
11231991 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Morphological and immunohistochemical studies revealed that the primary and recurrent pituitary tumours and the metastatic lesion were an endocrine tumour with ACTH and growth hormone immunoreactivity.
|
11678840 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, each cell line expressed the necessary receptors to respond to GH and the IGFs but there was no autocrine IGF production by the tumors themselves.
|
11472074 |
2001 |